Top Tech Companies (114)
Don't see your company?
Create a company profile
Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.
OnPoint Surgical is revolutionizing orthopedic and neurosurgical spinal procedures with an Augmented Reality (AR) platform technology that superimposes virtual surgical guides and virtual spinal implants onto the surgeon’s visual field using see-through optical head-mounted displays. The technology offers many unique clinical and intra-operative benefits including intuitive use, improved hand-eye coordination, and impressive accuracy with the potential for better clinical outcomes.
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.
Bioreactors and operating systems for the industrial production of cultivated meat
Colossal is a breakthrough bioscience and genetic engineering company that builds radical new technologies to advance the field of genomics. Colossal creates disruptive technologies for extinct species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. The company is the first to apply CRISPR technology for the purposes of species de-extinction, beginning with the woolly mammoth. Colossal is accepting humanity’s duty to restore Earth to a healthier state.
At Nimbus, we design breakthrough medicines. Utilizing our powerful structure-based drug discovery engine, we create potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. With a decade-plus track record of success, we’ve built a world-class team in both computationally driven drug discovery and early clinical development while continuing to move the needle for patients.
Strand was started by biological engineers working together at MIT. Building on the idea of creating smart therapies that are capable of making sophisticated decisions, they sought to apply the concept of the emerging field of mRNA therapeutics. This area was untapped by traditional synthetic biology, which led them to build their own mRNA “programming language,” creating the world’s first platform for mRNA smart therapies. Strand’s mRNA programming technology promises to make mRNA therapies safer and more effective by programming the location, timing, and intensity of therapeutic protein expression inside a patient’s body using mRNA-encoded logic circuits. These circuits can implement cell-type specific expression by sensing and classifying the unique miRNA expression signatures of cells, as well as controlling the dosage of protein expression by responding to exogenously administered small molecules.
At Scipher, we are relentlessly driven to solve one of healthcare’s biggest challenges and improve patient health outcomes. Scipher’s mission is to match each autoimmune patient with their most effective therapy. Each year, hundreds of billions of dollars are wasted prescribing drugs of limited clinical benefit to patients, even though there are often effective alternative therapies available. We believe there is a better way.
Reverie Labs is a pharmaceutical company that uses its innovative computational chemistry and machine learning tools to accelerate its drug discovery programs. Reverie's primary goal is to develop kinase inhibitors that address the unmet needs of patients.
High Touch Group is a privately held consultancy that helps science, engineering, and technology clients market existing products and services, showcase their value, develop and launch new products, engage with investors, generate leads, and drive revenue. We keep the science and make it exciting.
Intelon Optics, Inc. is a medical device company focusing on the development and commercialization of the Brillouin Optical Scanner System, or BOSS™, a technology that enables revolutionary, point-by-point biomechanics imaging of eye structures extending from the front of the eye, or the cornea, to the back of the eye, empowering eye care professionals to make treatment decisions with confidence based on biomechanical tissue properties.
SiPhox is a high-impact startup in Burlington, MA integrating microfluidics, biochemistry and Silicon Photonics to miniaturize proteomics. Silicon Photonics is a platform technology for optics miniaturization that has revolutionized the data center industry over the last two decades. SiPhox’s photonic chips enable us to provide 100x smaller, 100x lower cost, highly scalable, multiplexed diagnostics. Founded in February 2020, SiPhox has expanded into an over 7000 sq. ft. lab & office space, raised $8.5 million (seed round, from backers such as Y-combinator and Khosla Ventures), and we are tirelessly working to scale our team and bring our product to market.
At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients. We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured.
Applied Pathology Systems is a Histopathology laboratory in Greater Boston that provides cutting-edge histology services and has a strong reputation for preparing, embedding, staining, and interpreting tissue sections. The laboratory is CLIA certified and led by experienced histologists working under the guidance of US board-certified pathologists. APS offers general histology, immunohistochemistry, digital imaging & analysis, pathology evaluation, and surgical pathology consultations. Human and veterinary board-certified pathologists specialize in Gastroenterology and Dermatology with years of subspeciality training.
We are an R&D company with exclusively licensed and patent pending technology to replenish mitochondria to fight disease, including neurodegenerative disorders such as ALS, Alzheimer’s, and Parkinson’s.
We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF.
